Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

PTC Therapeutics Q3 2026 Results: Net Loss of $51.7M

For the nine months ended September 30, 2026, PTC Therapeutics reported total revenues of $990.9 million and net income of $29.0 million, a significant decrease from the $817.6 million net income in the prior year period which was bolstered by high collaboration revenue. The company's balance sheet remains strong with $2.1 billion in cash, cash equivalents, and marketable securities, though it maintains a total stockholders' deficit of $191.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue357.8211.0
Profit before tax-41.1-23.1
Net income-51.715.9
EPS (diluted, $ a share)$-0.62$0.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+69.6%
Operating margin7.0%
Source

10-Q filed with the SEC, NASDAQ: PTCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

PTC Therapeutics, Inc.: key numbers

Share price
$60.97Close, Nov 16
Market cap
$5.09B
Shares outstanding
83.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from PTC Therapeutics, Inc.

All →
9:01 AM ET 8-K
Stock Buyback

PTC Therapeutics Announces $500M Stock Buyback

PTC Therapeutics announced that its Board of Directors has authorized a share repurchase program to buy back up to $500 million of its common stock. The repurchases will be conducted at management's discretion through open-market or privately negotiated transactions based on market conditions.

Value
$500M
4:11 PM ET 8-K
Financial Results

PTC Therapeutics Financial Results

PTC Therapeutics reported record third-quarter 2026 financial results, with total revenue reaching $358 million, driven by $182 million in sales from the Sephience launch. The company raised its full-year 2026 revenue guidance to a range of $1.29 billion to $1.32 billion and expects to complete its BLA submission for the ST-920 Fabry disease gene therapy in Q4 2026.

“We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”

Matthew B. Klein, M.D., Chief Executive Officer
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Michael Schmertzler Sells $149K of Stock

Michael Schmertzler, Director, sold 2,500 shares of PTC Therapeutics, Inc. at $59.52 to $60.14 a share (average $59.61) in 2 transactions, worth $149K in total on Oct 14, 2026. Shares held after the trade: 1,291,594 (-0.0%).

Value
$149K
Shares
2,500
Average price
$59.61
Role
Director
Holding change
-0.0%
Trade date
Oct 14, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $12.3K of Stock

Mark Elliott Boulding, Exec. VP and CLO, sold 192 shares of PTC Therapeutics, Inc. at $64.26 a share, worth $12.3K in total on Oct 9, 2026. Shares held after the trade: 105,272 (-0.2%).

Value
$12.3K
Shares
192
Price
$64.26
Role
Exec. VP and CLO
Holding change
-0.2%
Trade date
Oct 9, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Michael Schmertzler Sells $155K of Stock

Michael Schmertzler, Director, sold 2,447 shares of PTC Therapeutics, Inc. at $63.38 a share, worth $155K in total on Oct 7, 2026. Shares held after the trade: 1,294,147 (-0.2%).

Value
$155K
Shares
2,447
Price
$63.38
Role
Director
Holding change
-0.2%
Trade date
Oct 7, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $133K of Stock

Mark Elliott Boulding, Exec. VP and CLO, sold 2,073 shares of PTC Therapeutics, Inc. at $64.03 to $64.16 a share (average $64.06) in 2 transactions, worth $133K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 105,272 (-0.4%).

Value
$133K
Shares
2,073
Average price
$64.06
Role
Exec. VP and CLO
Holding change
-0.4%
Trade date
Oct 5, 2026 to Oct 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.